Immunocore Holdings plc (IMCR)

53.78 +1.20 (+2.28%) 市場開市。 截至 11:48AM EST。

Immunocore Holdings plc

92 Park Drive
Milton Park
Abingdon OX14 4RY
United Kingdom
44 12 3543 8600
https://www.immunocore.com

版塊: Healthcare
行業: Biotechnology
全職員工: 408

高階主管

名稱	頭銜	支付	行使價	出生年份
Dr. Bahija Jallal Ph.D.	CEO & Director	1.42M	無	1962
Mr. Brian R. Di Donato M.B.A.	CFO & Head of Strategy	無	無	1967
Ms. Annelise Vuidepot Ph.D.	CTO and Head of Pipeline & Platform Research	無	無	無
Clayton Robertson	Head of Investor Relations	無	無	無
Ms. Lily Margaret Hepworth	General Counsel & Company Secretary	無	無	無
Ms. Amy Judge-Prein	Chief Compliance Officer	無	無	無
Mr. Sébastien Desprez	Head of Communications	無	無	無
Ms. Tina St. Leger	Chief Human Resources Officer & Director	無	無	1968
Dr. David Berman M.D., Ph.D.	Head of Research & Development	無	無	1971
Ms. Debra Nielsen	Chief of Staff	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma, ovarian, non-small cell lung cancer, and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C, which is for a range of tumors, including colorectal, gastro-esophageal, and pancreatic cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

公司管治

截至 無 止，Immunocore Holdings plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。